1. Home
  2. EU vs AGEN Comparison

EU vs AGEN Comparison

Compare EU & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$1.24

Market Cap

306.9M

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.51

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EU
AGEN
Founded
2009
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.9M
274.8M
IPO Year
2011
1999

Fundamental Metrics

Financial Performance
Metric
EU
AGEN
Price
$1.24
$7.51
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$4.00
$14.50
AVG Volume (30 Days)
3.4M
990.1K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
100.00
EPS
N/A
0.96
Revenue
$43,155,000.00
$42,877,086.00
Revenue This Year
$212.11
$107.63
Revenue Next Year
$29.88
N/A
P/E Ratio
N/A
$7.74
Revenue Growth
N/A
89.95
52 Week Low
$1.03
$2.71
52 Week High
$4.19
$8.85

Technical Indicators

Market Signals
Indicator
EU
AGEN
Relative Strength Index (RSI) 49.88 52.38
Support Level $1.03 $7.50
Resistance Level $1.47 $8.70
Average True Range (ATR) 0.09 0.58
MACD 0.00 -0.10
Stochastic Oscillator 43.62 21.05

Price Performance

Historical Comparison
EU
AGEN

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: